Intomics will assist Lundbeck with methods and tools for analysing and integrating large quantities of biological data generated in the drug development process. Intomics CEO Thomas Jensen said
Prior to joining Kite Pharma, Lee has worked as the vice president of Clinical Development at Syndax Pharmaceuticals. Kite Pharma president and CEO Aya Jakobovits said that he
Prima BioMed has received the status under the generic name Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein (Mucin1- Glutathione S Transferase) Coupled To Oxidised Polymannose for
Elder Pharmaceuticals already owns 21.1% stake in NeutraHealth. NeutraHealth, which has three group companies – Biocare, Brunel Healthcare and Totally Nourish, focuses on vitamins, minerals and supplements sector
In the study it was observed that the maximal tolerated dose of Inecalcitol is 4mg per day and the response rate to combination treatment reached 85% based on
Oracle claimed that Agile PLM 9.3.1 provides deeper product lifecycle analytics, next generation multi-CAD integrations, complex technical documents management, design variant management and other usability and functional enhancements.
The drug blocks the recently discovered clacitonin-gene related hormone receptor (CGRP), a vasodilator protein believed to be a key player in migraine. Merck initiated the development of Telcagepant
Ligand is expected to receive an upfront payment and continue to be entitled to receive potential future milestone and royalty payments. Ligand Pharma president and CEO John Higgins
Afatinib is an oral compound targeted therapy that irreversibly inhibits both the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour
Genentech’s information submitted to the FDA during the review of the sBLAs for Avastin for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.